Finding the Right Balance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Finding the Right Balance

Equipment and Processing Report

Untitled Document

Q: When a pharmaceutical quality-control or quality-assurance laboratory weighs a monogrammed substance for assay, the balance used to weigh the sample must conform to the requirements laid out in US Pharmacopeia <41>. How do you assign a minimum sample weight for a USP <41> balance application when the tested repeatability gives a standard deviation (SD) of zero?

A: The idea that 0 SD for a repeatability test means an excellent result is a misconception. In fact, 0 SD indicates a problem with the choice of instrument or methodology used for the test.

If a measuring instrument indicates a 0 SD during testing, it does not have enough sensitivity to measure the tested mass accurately. Because most balances used for USP <41> applications are analytical balances (i.e., those with 0.1 or 0.01mg readability), a result of 0 SD during a repeatability test should never be considered a pass criterion for minimum-weight verification. The same can be said for micro and ultramicro balances (i.e., those with 1 or 0.1µg readability). A 0 SD generally means that the balance does not have enough displayed digits (i.e., readability) for the tested minimum weight. USP <41> recommends a limit of 0.1% error in the measurement. If the balance cannot display 0.1% of the desired minimum weight, then testing for suitability is pointless because you cannot meet the USP requirements.

Course-reading top-loader balances sometimes give a 0 SD result during minimum-weight tests. The problem is that top-loader balances of low readability (e.g., 0.1 or 0.01 g) are inherently insensitive because of their course readability. The theoretical test mass needed to achieve suitable sensitivity levels with such an instrument may be way beyond the balance’s actual capacity. In compliance with current legislation, the correct solution is to employ a balance with the correct readability to display 0.1% of the net sample under investigation.

—Ian Ciesniewski, technical director at Mettler Toledo

 

If you have a problem with your equipment or process, an industry expert may have the solution. Please send your question to Erik Greb, editor of Equipment and Processing Report, and we may be able to provide an answer in a future issue. All questions will remain anonymous.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: Equipment and Processing Report,
Click here